ArticleInternational journal of trichology
Peroxisome Proliferator-activated Receptor Gamma Serum Levels and Gene Polymorphism in Frontal Fibrosing Alopecia: A Case-Control Study.
Article in International journal of trichology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Frontal fibrosing alopecia (FFA) is a scarring alopecia with a complex pathogenesis that is not completely clear yet. Objective: The aims of the study were to evaluate serum peroxisome proliferator-activated receptor gamma (PPARγ) levels and gene polymorphism in a sample of Egyptian FFA patients. Subjects and Methods: The case-control study included 93 FFA female patients and 157 matching apparently healthy control subjects. Patients were subjected to clinical and trichoscopic examinations to diagnose FFA according to the updated diagnostic criteria. FFA severity was evaluated using the FFA Severity Index (FFASI). Serum PPARγ levels and gene polymorphisms were assessed in all participants using enzyme-linked immunosorbent assay and polymerase chain reaction techniques, respectively. Results: Serum PPARγ levels in the patients' group were significantly lower than that of the control subjects' group. PPARG (Pro12Ala) gene polymorphism was significantly predominant in FFA patients when compared to the control subjects. Patients carrying polymorphic genotypes showed significantly reduced serum PPARγ levels when compared to patients carrying the wild genotype. They also showed significantly higher FFASI in comparison to wild genotype carriers. Conclusion: PPARγ may play an important role in FFA development. It might have a potential utility as a biomarker in FFA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.